亚细胞蛋白质组学对阿尔茨海默氏症疾病发展的洞察
Zhiyuan Liang1, Hongbin Zhuang1, Xueshan Cao1,2
1College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, P. R. China.
Proteomics. Clinical applications
|August 31, 2023
概括
蛋白质组学揭示了阿尔茨海默病 (AD) 发病过程中的关键分子变化,包括线粒体功能障碍和蛋白质聚合物. 这项研究有助于识别AD的新生物标志物和治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,患病率越来越高.
- 目前对AD分子机制和有效治疗方法的理解仍然有限.
- 蛋白质组学提供了一种全面的方法来研究AD的病原性.
研究的目的:
- 审查基于质谱 (MS) 的蛋白质组学在理解阿尔茨海默病中的应用.
- 专注于亚细胞蛋白学研究AD,包括线粒体,突触和蛋白质聚合物.
- 突出蛋白质组学在识别AD生物标志物和药物标方面的潜力.
主要方法:
- 使用基于质谱 (MS) 的公正蛋白质组学.
- 分析子细胞组件中的蛋白质变化:线粒体,突触,髓,粉状斑块 (AP),神经纤维状 (NFT),细胞外囊泡 (EV),外体,核糖体和溶酶体.
- 审查样品分离,制备和蛋白质组分析技术.
主要成果:
- 蛋白质组学研究已经阐明了与AD相关的线粒体功能障碍,突触损伤和髓分解.
- 对粉样质斑块和神经纤维状团中的蛋白质组成的分析为AD病理学提供了洞察力.
- 细胞外囊泡,外酶体,核糖体和溶酶体的变化揭示了AD的进一步分子变化.
结论:
- 蛋白质组学提供了对阿尔茨海默氏症病原体背后的分子机制的关键见解.
- 这些发现为未来的AD研究提供了理论基础和方向.
- 蛋白质组数据可以在发现新生物标志物和AD治疗点方面发挥重要作用.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
531
10:51Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting
Published on: April 10, 2014
16.1K
相关概念视频
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212